North America Ophthalmic Drugs And Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Aging Population and Cataract–Glaucoma Burden

By 2030, the 65-plus population in North America will total 83 million, representing a 35% jump from 2020 and accounting for 92% of age-related macular degeneration cases and 78% of primary open-angle glaucoma cases.^{[1]U.S. Census Bureau, “Projected Age Demographics,” census.gov} Cataract prevalence among Americans older than 75 climbed to 68% in 2024, up from 61% five years earlier, reflecting longer life expectancy and higher diabetes incidence. Canada’s National Institute on Ageing projects that seniors will make up one-quarter of the population by 2030, a shift already stretching cataract wait-lists that average 6.2 months in Ontario and British Columbia. Mexico’s aging curve lags but accelerates after 2028, prompting cross-border demand for U.S. procedures as the 60-plus cohort grows at 4.1% annually. This demographic momentum sustains steady cataract and glaucoma procedure pipelines that, in turn, support equipment upgrades and sustained drug dispensing.

Technological Advances in Minimally Invasive Surgery

Femtosecond laser-assisted cataract surgery penetrated 38% of U.S. premium cases in 2025 because blade-free capsulotomies cut posterior capsule rupture risk to 0.14% versus 0.92% for manual techniques. The iStent Infinite, cleared in 2024, places three micro-bypass stents through one injector and achieved an 18 mmHg mean intraocular pressure drop at 12 months in the APEX study. Lensar’s ALLY system overlays augmented-reality guidance on real-time OCT and was adopted by 127 U.S. ASCs in ten months. Canada reimburses FLACS only with premium IOLs, so 62% of 2025 cases were private-pay. 

AI Powered Diagnostic Imaging Adoption

The FDA cleared 14 autonomous ophthalmic AI algorithms between January 2024 and December 2025, including EyeArt for diabetic retinopathy screening in primary care offices.^{[2]U.S. Food and Drug Administration, “De Novo and 510(k) Decisions 2024-2025,” fda.gov} Notal Vision’s Home OCT lets AMD patients scan weekly at home, reducing clinic visits by 40% in a Veterans Affairs pilot involving 890 participants. By mid-2025, autonomous DR screening operated in 2,300 U.S. clinics, delivering 1.8 million scans and tripling referral rates compared with manual fundus review. Ontario integrated IDx-DR at 89 remote Indigenous health centers, diagnosing referable disease in 11.3% of adults and saving CAD 4.2 million in travel outlays. The FDA draft SaMD guidance issued in 2025 now requires post-market monitoring for algorithm drift when real-world demographics diverge from training data by more than 15%.

Outpatient ASC Procedure Growth

Ophthalmic cases performed in ASCs accounted for 21% of total U.S. volume in 2024, up from 16% in 2020, because site-neutral payments made lower-overhead facilities more profitable. The 2025 Physician Fee Schedule raised ASC reimbursement for complex cataract by 12% while hospital outpatient rates stayed flat.^{[3]Centers for Medicare & Medicaid Services, “2025 Physician Fee Schedule Final Rule,” cms.gov} Sg2 forecasts ASC ophthalmic demand will climb another 21% through 2029, helped by Medicare Advantage plans that steer beneficiaries toward contracted ASCs. Alberta, British Columbia, and Quebec now allow private ASCs for cataract, yet fee schedules pay only 78% of hospital tariffs, limiting penetration to 18%. Mexico licensed 23 new ophthalmic ASCs in 2024, mostly in Monterrey, Guadalajara, and Tijuana, to serve inbound medical tourists.

High Cost of Advanced Devices & Limited Procedure Reimbursement

A fully equipped ophthalmic ASC requires USD 1.2-2.5 million for a femtosecond laser, swept-source OCT, phaco system, and microscope, making entry into the market tough for independents. Alcon’s Centurion system is listed at USD 135,000 in 2025, whereas J&J’s Catalys laser costs USD 650,000 or USD 9,500 monthly under a seven-year lease. Independent ASCs doing fewer than 800 cataract cases a year face payback periods of more than 4 years. Canadian capital budgets fell 8% in real terms from 2020-2024, forcing hospitals to stretch equipment cycles to 15 years. Mexico’s clinics pay 12-18% import tariffs on U.S. devices, raising landed costs outside major metros.

Stringent FDA Approval Timelines

Median 510(k) ophthalmic review duration extended to 187 days in 2024 as CDRH requested more AI evidence. Class III PMA devices averaged 18.3 months, and 34% drew major deficiency letters. Smaller firms shoulder USD 1.2-3.5 million per filing, a burden that narrows disruptive pipelines. Health Canada mirrors FDA data requirements and adds separate provincial reimbursement dossiers, which can lengthen launches by up to 14 months. COFEPRIS adopted a 90-day fast track for Class II but still requires 12-18 months for implants, widening diagnostic–surgical asymmetry.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

North America Ophthalmic Drugs And Devices Market Segment Analysis

Diagnostics commanded 51.12% of 2025 revenue as swept-source OCT, fundus cameras and rebound tonometers became standard equipment in 92% of new office installations. The drug class will grow at 6.33% through 2031, overtaking hardware, as anti-VEGF biosimilars and novel dry-eye agents expand therapeutic volumes. Surgical devices grew 4.1% in 2024-2025 as premium toric and EDOF lenses lifted procedure revenue despite saturated monofocal demand. Vision care products face refractive-surgery headwinds, yet gain from myopia-control offerings aimed at children.

Swept-source OCT platforms such as Zeiss Cirrus 6000 displaced time-domain systems largely because 1050 nm wavelengths penetrate dense cataracts and capture 100,000 A-scans per second, a leap that enables widefield angiography. Fundus cameras integrating AI diabetic retinopathy software reached 41% of U.S. primary care deployments by mid-2025. Intraocular lens innovation is anchored by light-adjustable materials; RxSight’s LAL secured 12% of U.S. premium placements in 2025. 

Cataract retained 32.05% of application revenue in 2025 on 4.2 million U.S. surgeries and remains the volume anchor through 2031. Glaucoma, however, will climb at an 8.63% CAGR as MIGS shifts surgery earlier; 32% of glaucoma operations used MIGS in 2025 compared with 18% in 2021. Retinal disorders generated 19% of revenue, with injection counts rising to 7.8 million annually. Refractive procedures have shifted from LASIK to SMILE, which now accounts for 28% of cases.

ASC economics favor cataract migration, with Medicare paying USD 1,138 per routine phaco case in ASCs versus USD 1,847 in hospitals. Premium lenses command USD 1,200-2,500 out-of-pocket per eye, bolstering surgeon income. MIGS devices lower mean IOP by roughly 25% and carry a lower complication risk than trabeculectomy, widening candidacy. Retinal reimbursement compression accelerates the adoption of longer-acting agents that stretch dosing to 12-16 weeks. 

Hospitals and eye clinics delivered 54.12% of 2025 revenue but will cede share as specialty ophthalmic centers grow 10.11% through 2031 under private-equity ownership models that unify workflows and centralize purchasing. ASCs already perform 21% of ophthalmic procedures and gain a cost advantage from lower overhead, with operating costs averaging 42% of hospital outpatient equivalents. 

Leasing has become the capital strategy of choice; 64% of ASCs opened in 2024-2025 leased lasers and OCT under 7-year agreements, slashing upfront spend to USD 12,000-15,000 per month. Medicare sequestration and nursing wage inflation shrink hospital cataract margins, hastening volume flight. Canadian formularies constrain private differentiation, while Mexico’s online pharmacy market remains nascent due to COFEPRIS script-verification rules.

Geography Analysis

United States Ophthalmic Drugs And Devices Market

The United States accounted for 81.78% of regional revenue in 2025, driven by 14,800 practices, 4.2 million cataract surgeries, and 7.8 million anti-VEGF injections. Premium segments drive U.S. upside as toric and multifocal lenses generated USD 1.9 billion in out-of-pocket spend, and femtosecond cataract technology added USD 680 million. Medicare Advantage enrollment hit 54% and steers two-thirds of beneficiaries to contracted ASCs, deepening consolidation. FDA granted 11 Breakthrough Device designations to ophthalmic innovations during 2024-2025, reinforcing the country’s launch primacy.

Canada Ophthalmic Drugs And Devices Market

Biosimilar ranibizumab reduced injection costs by 38% yet specialist wait times still exceed eight weeks in major provinces. Private clinics account for 34% of cataract cases with premium lenses, as public queues average 6.2 months. Device launches lag U.S. time-lines by up to 14 months due to separate CADTH health-technology assessments.

Mexico Ophthalmic Drugs And Devices Market

Mexico is poised for 8.26% CAGR, the region’s fastest, propelled by medical tourism that drew 42,000 U.S. patients in 2024 and expanding private insurance that now covers 29% of citizens. COFEPRIS licensed 23 new ophthalmic ASCs in 2024. LASIK prices remain 40-55% below U.S. levels, pulling cross-border volume. Class II device approvals were harmonized with FDA to 90 days, yet Class III implants still wait up to 18 months. IMSS public hospital backlogs push middle-income patients toward private options, accelerating demand for premium technology.

Regulatory Landscape

In the United States, ophthalmic products that combine a drug with a delivery component (such as certain dispensers packaged with ophthalmic drugs) can be regulated as combination products, with jurisdiction determined by the primary mode of action under 21 CFR Part 3. For drug-led combinations, manufacturers must comply with the combination-product cGMP framework under 21 CFR Part 4, aligning pharmaceutical GMP controls with device quality-system requirements in a single quality approach, which is particularly relevant for drug-device delivery formats used in dry-eye, glaucoma, and presbyopia drops.

In Canada, Health Canada routes classification questions for complex products through mechanisms such as the Therapeutic Products Classification Committee (TPCC), which supports determinations of whether a product is regulated as a drug, device, or drug-device combination product under the Food and Drugs Act and associated regulations. This up-front classification step influences evidence packages and the downstream sequence of federal review and provincial reimbursement files, a practical consideration for suppliers launching cross-border portfolios in North America.

Market Opportunities and Future Outlook

Combination-style ophthalmic therapies and delivery formats represent an active whitespace where product differentiation ties directly to regulatory execution and manufacturing capability. FDA approval of Tenpoint Therapeutics YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) for adult presbyopia in January 2026 highlights continued innovation in multi-ingredient ophthalmic solutions, while FDA approval activity for ophthalmic generics such as Alembic Pharmaceuticals loteprednol etabonate and tobramycin ophthalmic suspension (ANDA, Competitive Generic Therapy designation, December 2025) signals sustained competitive pressure in mature anti-infective and anti-inflammatory classes.

Operationally, the U.S. combination-product framework under 21 CFR Part 4 creates opportunity for developers and suppliers that build robust primary mode of action (PMOA) strategies early and partner with contract manufacturers capable of operating dual-regime quality systems for both drug and device elements. As autonomous imaging and home monitoring expand within care pathways (for example, diabetic retinopathy screening in primary care and home OCT pilots), software-enabled diagnostics and workflow tools that integrate with ophthalmology practices and ASCs create additional commercial space for platforms that reduce technician burden and increase throughput.